Primary pulmonary adenocarcinoma in a 16-year-old boy – a five-year follow-up

References

• Yu DC, Grabowski MJ, Kozakewich HP, Perez-Atayde AR, Voss SD, Shamberger RC, etal. Primary lung tumors in children and adolescents: a 90-year experience. J Pediatr Surg. 2010; 45: 1090–5.
   Web of Science ®Google Scholar
• Rojas Y, Shi YX, Zhang W, Beierle EA, Doski JJ, Goldfarb M, etal. Primary malignant pulmonary tumors in children: a review of the national cancer data base. J Pediatr Surg. 2015; 50: 1004–8.
   Web of Science ®Google Scholar
• Hartman GE, Shochat SJ. Primary pulmonary neoplasms of childhood: a review. Ann Thorac Surg. 1983; 36: 108–19.
   PubMed Web of Science ®Google Scholar
• Hancock B, Di Lorenzo M, Youssef S, Yazbeck S, Marcotte J, Collin P. Childhood primary pulmonary neoplasms. J Pediatr Surg. 1993; 28: 1133–6.
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, etal. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009; 374: 1432–40.
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, etal. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012; 13: 300–8.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, etal. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123–32.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, etal. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013; 14: 981–8.
   PubMed Web of Science ®Google Scholar
• Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, etal. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer. 2013; 119: 2754–64.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, etal. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368: 2385–94.
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, etal. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 1589–97.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, etal. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18: 2095–3.
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, etal. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007; 99: 847–57.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, etal. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543–51.
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, etal. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27: 1227–34.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, etal. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92–8.
   PubMed Web of Science ®Google Scholar
• Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, etal. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013; 24: 20–30.
   PubMed Web of Science ®Google Scholar
• Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, etal. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 2009; 20: 1249–56.
   PubMed Web of Science ®Google Scholar
• Helbekkmo N, Sundstrom SH, Aasebo U, Brunsvig PF, von Plessen C, Hjelde HH, etal. Vinorelbine/carboplatin vs. gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer. 2007; 97: 283–9.
   PubMed Web of Science ®Google Scholar
• Kerner GS, Schuuring E, Sietsma J, Hiltermann TJ, Pieterman RM, de Leede GP, etal. CTMM Air Force Consortium. Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome. PLoS One. 2013; 70346. http://dx.doi.org/10.1371/journal.pone.0070346.
   Google Scholar
• Kato M, Onishi H, Matsumoto K, Tsuruta N, Higuchi K, Motoshita J, etal. Preoperative chemoradiotherapy using cisplatin plus S-1 can induce downstaging in patients with locally advanced (stage III) non-small-cell lung cancer. Anticancer Res. 2012; 32: 5099–104.
   Web of Science ®Google Scholar
• Aydiner A, Sen F, Saglam EK, Oral EN, Eralp Y, Tas F, etal. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study. Clin Lung Cancer. 2011; 12: 286–92.
   Web of Science ®Google Scholar
• Mordant P, Arame A, De Dominicis F, Pricopi C, Foucault C, Dujon A, etal. Which metastasis management allows long-term survival of synchronous solitary M1b non-small cell lung cancer?. Eur J Cardiothorac Surg. 2012; 41: 617–22.
   Web of Science ®Google Scholar
• Ettinger D, Wood D, Akerley W, Bazhenova L, Borghaei H, Camidge D, etal. Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 2015; 13: 515–24.
   PubMed Web of Science ®Google Scholar